-
The paper was penned by a 26-year-old Swiss patent clerk with dark, curly hair years before he sprouted that signature nest of white hair.
NPR: E=mc? at 100
-
Healthcare campaigners have welcomed India's rejection of a legal bid by Swiss company Novartis to patent a new version of its cancer drug, Glivec.
BBC: Novartis India case: Campaigners hail patent rejection
-
"It is a landmark judgement, " Sakhtivel Selvaraj, a leading Delhi-based health economist, tells me, hours after the Indian Supreme Court's decision to reject a plea by Swiss pharmaceutical firm Novartis to patent an updated version of its cancer drug, Glivec.
BBC: Is Novartis ruling a watershed?
-
The Swiss drugmaker had been denied a patent on the grounds that the new version was only slightly different from the old.
BBC: Novartis case: Media hail 'key victory' for India
-
In 2006 India refused to grant a patent to Novartis, a Swiss drug giant, for Glivec, a blockbuster cancer drug, saying it was merely a new form of an older medicine.
ECONOMIST: Drugs and emerging markets: Tripped up | The
-
The Swiss pharmaceutical giant has fought a legal battle in India since 2006 to patent a new version of Glivec, which is mainly used to treat leukemia and is known as Gleevec outside India and Europe.
NPR: Drug Maker Novartis Loses India Patent Battle